217 related articles for article (PubMed ID: 7607565)
21. Metabolic polymorphisms and cancer susceptibility.
Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.
Hirvonen A
Environ Health Perspect; 1999 Feb; 107 Suppl 1(Suppl 1):37-47. PubMed ID: 10229705
[TBL] [Abstract][Full Text] [Related]
23. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
24. Molecular epidemiology and urothelial cancer.
Tsukino H; Omori H; Kohshi K; Yamano Y; Katoh T
J UOEH; 2007 Sep; 29(3):265-89. PubMed ID: 17900006
[TBL] [Abstract][Full Text] [Related]
25. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
26. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
27. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China.
Chen HC; Cao YF; Hu WX; Liu XF; Liu QX; Zhang J; Liu J
Dis Markers; 2006; 22(3):141-52. PubMed ID: 16788248
[TBL] [Abstract][Full Text] [Related]
29. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens.
Le Marchand L; Sivaraman L; Pierce L; Seifried A; Lum A; Wilkens LR; Lau AF
Cancer Res; 1998 Nov; 58(21):4858-63. PubMed ID: 9809991
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
McGrath M; Michaud D; De Vivo I
BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.
Zgheib NK; Shamseddine AA; Geryess E; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; El-Saghir NS
Mutat Res; 2013; 747-748():40-7. PubMed ID: 23628324
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer.
Kiyohara C
J Epidemiol; 2000 Sep; 10(5):349-60. PubMed ID: 11059519
[TBL] [Abstract][Full Text] [Related]
34. Metabolism of xenobiotics and chemical carcinogenesis.
Lang M; Pelkonen O
IARC Sci Publ; 1999; (148):13-22. PubMed ID: 10493245
[TBL] [Abstract][Full Text] [Related]
35. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach.
Castell JV; Donato MT; Gómez-Lechón MJ
Exp Toxicol Pathol; 2005 Jul; 57 Suppl 1():189-204. PubMed ID: 16092727
[TBL] [Abstract][Full Text] [Related]
36. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
Chacko P; Joseph T; Mathew BS; Rajan B; Pillai MR
Mutat Res; 2005 Mar; 581(1-2):153-63. PubMed ID: 15725614
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.
Mota P; Silva HC; Soares MJ; Pego A; Loureiro M; Cordeiro CR; Regateiro FJ
J Cancer Res Clin Oncol; 2015 May; 141(5):851-60. PubMed ID: 25388590
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility.
Hatagima A
Cad Saude Publica; 2002; 18(2):357-77. PubMed ID: 11923879
[TBL] [Abstract][Full Text] [Related]
39. [Prevention of renal carcinoma: the nutri-genetic approach].
Junien C; Dupret JM; Gallou C; Longuemaux S; Richard S; Saquet C; Krishnamoorty R; Delomenie C; Droz D; Bouvier R; Chauveau D; Joly D; Grunfeld JP; Chretien Y; Mejean A; Beroud C
J Soc Biol; 2000; 194(1):29-38. PubMed ID: 11107547
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphism of drug metabolizing enzymes (GSTM1 and CYP1A1) as risk factors for oral premalignant lesions and oral cancer.
Shukla D; Dinesh Kale A; Hallikerimath S; Vivekanandhan S; Venkatakanthaiah Y
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Sep; 156(3):253-9. PubMed ID: 22660220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
